Short-term exposure to an obesogenic diet during adolescence elicits anxiety-related behavior and neuroinflammation: modulatory effects of exogenous neuregulin-1

Julio David Vega-Torres1,5, Perla Ontiveros-Angel1,5, Esmeralda Terrones1, Erwin C. Stuffle1, Sara Solak2, Emma Tyner2, Marie Oropeza2, Ike dela Peña3, Andre Obenaus3, Byron D. Ford4 and Johnny D. Figueroa5

© The Author(s) 2022

INTRODUCTION
Childhood obesity leads to hippocampal atrophy and altered cognition. However, the molecular mechanisms underlying these impairments are poorly understood. The neurotrophic factor neuregulin-1 (NRG1) and its cognate ErbB4 receptor play critical roles in hippocampal maturation and function. This study aimed to determine whether exogenous NRG1 administration reduces hippocampal abnormalities and neuroinflammation in rats exposed to an obesogenic Western-like diet (WD). Lewis rats were randomly divided into four groups (12 rats/group): (1) control diet+vehicle (CDV); (2) CD + NRG1 (CDN) (daily intraperitoneal injections: 5 μg/kg/day; between postnatal day, PND 21-PND 41); (3) WD + VEH (WDV); (4) WD + NRG1 (WDN). Neurobehavioral assessments were performed at PND 43–49. Brains were harvested for MRI and molecular analyses at PND 49. We found that NRG1 administration reduced hippocampal volume (7%) and attenuated hippocampal-dependent cued fear conditioning in CD rats (56%). NRG1 administration reduced PSD-95 protein expression (30%) and selectively reduced hippocampal cytokine levels (IL-33, GM-CSF, CCL-2, IFN-γ) while significantly impacting microglia morphology (increased span ratio and reduced circularity). WD rats exhibited reduced right hippocampal volume (7%), altered microglia morphology (reduced density and increased lacunarity), and increased levels of cytokines implicated in neuroinflammation (IL-1α, TNF-α, IL-6). Notably, NRG1 synergized with the WD to increase hippocampal ErbB4 phosphorylation and the tumor necrosis alpha converting enzyme (TACE/ADAM17) protein levels. Although the results did not provide sufficient evidence to conclude that exogenous NRG1 administration is beneficial to alleviate obesity-related outcomes in adolescent rats, we identified a potential novel interaction between obesogenic diet exposure and TACE/ADAM17-NRG1-ErbB4 signaling during hippocampal maturation. Our results indicate that supraoptimal ErbB4 activities may contribute to the abnormal hippocampal structure and cognitive vulnerabilities observed in obese individuals.

Translational Psychiatry (2022)12:83; https://doi.org/10.1038/s41398-022-01788-2
autonomous NRG1-specific activated tyrosine kinase, plays a critical role in regulating brain development and homeostasis. NRG1-ErbB4 signaling has been heavily implicated in neuronal migration, synaptic plasticity, and cognition [25]. NRG1-ErbB4 signaling regulates hippocampal function through increasing neuronal arborization [26], increasing gamma oscillations in the CA3 region of the hippocampus [27], modulating long-term potentiation at CA1 hippocampal synapses [28], and modifying stress reactivity and behavior [29–31]. Exogenous NRG1 administration increases hippocampal neurogenesis [32, 33] and improves learning and memory while rescuing dendritic and synaptic abnormalities in a mouse model of Alzheimer’s disease (AD) [34]. Similar neurorestorative properties were reported in a rat model of AD [35]. In addition, exogenous NRG1 administration confers potent anti-inflammatory effects. We and others have demonstrated that NRG1 anti-inflammatory actions extend to models of neuroinflammation, including cerebral malaria [36], nerve agent intoxication [37], and ischemia [38]. Studies demonstrate that ErbB4 inhibition attenuates the beneficial effects of NRG1, supporting an essential role for ErbB4 in NRG1 actions [39–42].

In this study, we hypothesized that NRG1 administration would confer protection against the detrimental effects of an obesogenic diet on neuroinflammation, hippocampal maturation, and anxiety-like behaviors. We reasoned that examining the responses of the hippocampal NRG1-ErbB4 system to obesogenic diets during adolescence may provide valuable insights into the potential contribution of this pathway to obesity-induced hippocampal deficits and anxiety. This study is the first to investigate whether exogenous NRG1 possesses the therapeutic potential to prevent the early consequences of an obesogenic environment during adolescence.

**MATERIALS AND METHODS**

**Animals**

All the experiments were performed following protocol #20-171 approved by the Institutional Animal Care and Use Committee (IACUC) at the Loma Linda University Health School of Medicine. This study follows the ARRIVE guidelines for reporting animal research [43]. Female Lewis rats with 8-10 male pups (postnatal day, PND 15) were purchased from Charles River Laboratories (Portage, MI, USA). Upon arrival, female rats were housed with their pups with free access to food and water. At PND 21, adolescent male pups were weaned, housed in groups (2 per cage), and experimental manipulations commenced. Animals were kept in customary housing conditions (21 ± 2 C, relative humidity of 45%, and...
12-hour light/dark cycle with lights on at 7:00 AM). The body weights were recorded once a week or daily during the week of behavioral testing. Food consumption was quantified at least twice per week. Uneaten food pellets (cage top and spillage) were weighted and recorded to the nearest 0.1 g. Subsequently, fresh food was added to the top of the cage (60 g). Food intake was expressed as an average of food weight per day. The food consumed was calculated at the same time of the day (0900-1100 h) for the duration of the study. The rats were never food or water restricted.

Study Design
We used a 2 × 2 design with four groups: (1) Control diet, injected with vehicle (CD + VEH); (2) Control diet, injected with neuregulin-1 (CD + NRG1); (3) Western diet, injected with vehicle (WD + VEH); (4) Western diet, injected with neuregulin-1 (WD + NRG1). Figure 1 summarizes the timeline of experimental procedures and behavioral tests. The matched were obtained from Bio-Serv (Frenchtown, NJ, USA). The macronutrient #F7462 short half-life in plasma [46, 47]. Recombinant human NRG1-effects of this intervention [37, 45], NRG1 biodistribution, kinetics, and between 12:00-1:00 PM. The rationale for injection dosage and route ters were blinded to the treatment conditions. Figure1 summarizes the 1 EGF domain (NRG1) was provided by Dr. Byron D. Ford (manufactured #F7463 and Western-like high-saturated fat diet (WD, 20-gm% fat, product #F7462) were obtained from Bio-Serv (Frenchtown, NJ, USA). The macronutrient composition and fatty acid profiles are detailed in a previous study and summarized in Supplemental Table 1 [44]. Weight-matched adolescent rats (PND 21-49) were divided into four groups: CD + VEH, CD + NRG1, WD + VEH, and WD + NRG1. NRG1 (5 micrograms/kilogram/day) or saline (vehicle) intraperitoneal injections were performed daily between 12:00-1:00 PM. The rationale for injection dosage and route was based on our previous reports describing the neuroprotective effects of this intervention [37, 45]. NRG1 biodistribution, kinetics, and short half-life in plasma [46, 47]. Recombinant human NRG1-β1/HRG1-β 1 EGF domain (NRG1) was provided by Dr. Byron D. Ford (manufactured by R&D Systems, catalog #396-HB-050). Study 1 (Fig. 1A:B: behavioral and anatomical assessment): All behavior testing sessions involved a 20-30-minute acclimation period to the testing facility. The rats were allowed to consume the custom diets until the completion of the study (PND 21-49). Guided by prior research [48], the initial group size was n = 18 for each group (divided into four cohorts). Twenty-four rats were randomly selected for MRI studies (n = 6 per group). Study 2 (Fig. 1C: molecular markers investigation): To minimize potential carryover effects between behavioral tests and molecular outcomes, we used a separate group of animals without behavioral manipulations for the molecular outcomes reported in this study (Western blot and flow cytometry). For this group, an additional injection of NRG1 or saline was administered 1 h before euthanizing the animals at PND 42 [46]. The initial group size for Study 2 was n = 5-6 for each group (CD + VEH, n = 5; CD + NRG1, n = 5; WD + VEH, n = 6; WD + NRG1, n = 6). Experimenters were blinded to the treatment conditions. Figure 1 summarizes the experimental procedures for each study.

Study 1 Behavioral test battery. We use a specific test battery to investigate phenotypic behavioral responses to stressors in rats that consume obesogenic diets. Our standard battery includes acoustic startle (and its stimulus, foot shock) and elevated plus-maze. Generally, behavioral tests are run from least to most invasive to minimize behavioral reactivity based on prior test history (carryover effects). However, a fundamental goal of our investigations is to understand precisely how previous experiences alter behavior. Specifically, we are interested in understanding how adolescent dietary obesity influences stress reactivity [18, 44, 48, 49]. Thus, in our battery, we have used foot shocks not only to promote fear conditioning but also as a stressor [44, 48, 49], as has been reported by others [50].

Fear-potentiated startle (FPS)
FPS rationale. The startle reflex is influenced by the corticolimbic system and modulated by both attentional and emotional states. Thus, the classic form of startle plasticity or fear-potentiated startle (FPS) represents a robust and reliable tool to assess cognitive and emotional aspects of fear reactivity. Given our prior work identifying the detrimental effects of the obesogenic diet on hippocampal structure and function [18], we used a trace FPS paradigm to evaluate hippocampal-dependent cue fear learning.

FPS apparatus. Startle responses were assessed inside the SR-Lab acoustic chambers (San Diego Instruments, Inc., San Diego, CA, USA). Each chamber contained a Plexiglas enclosure with a calibrated piezoelectric motion sensor. The startle reflex has a nonzero baseline and is graded in magnitude. Accelerometer readings were obtained at 1 ms intervals for 200 ms after the startle-inducing acoustic stimulus and recorded using SR-LAB startle software. Each enclosure had grid floors capable of delivering foot shocks (San Diego Instruments, CA).

FPS Training Session. During this Pavlovian fear conditioning paradigm, a neutral stimulus (light) elicits increases in the acoustic startle response after pairings with a foot shock. Each FPS session started with a 5-min acclimation period (background noise = 60 dB). During the first session of the footprint session (FPS training), the rats were trained to associate a light stimulus (conditioned stimulus, CS) with a 0.6 mA foot shock (unconditioned stimulus, US). The conditioning session involved 10 CS + US pairing presentations. During each CS + US presentation, the onset of the shock (500 ms duration) occurred 3 s after the offset of the 4 s light. This interval has been shown to recruit the hippocampus while producing similar startle responses as those observed in delay conditioned (REF). Light-shock pairings were presented in a quasi-random manner (ITI = 3-5 min).

FPS Testing Session. The cued fear acquisition was measured 24 h later. The testing session started with a brief 5 min acclimation period (background noise = 60 dB). During cued fear acquisition testing (fear learning testing), the rats were first presented with 15 startle-inducing tones (leaders; 5 each at 90 dB, 95 dB, and 105 dB) delivered alone at 30 s ITI. These leader trials were used to familiarize the rats with the acoustic stimuli, facilitating more accurate startle reactivity measurement during the session. Subsequently, the rats were presented with 60 test trials. For half of these test trials, a 20 ms tone was presented alone (tone alone trials; 10 trials for each tone: 90 dB, 95 dB, and 105 dB). For the other half, the tone onset (20 ms duration) occurred 3 s after the offset of the 4 s light; 10 trials for each pairing: 90 dB, 95 dB, and 105 dB. The 60 trials were divided into 10 blocks of six test trials each, including three tone alone trials and three light + tone trials. To conclude the testing session, the rats were presented with 15 startle-inducing tones (trailers; five each at 90 dB, 95 dB, and 105 dB) delivered at 30 s ITI. These trailer trials are commonly compared to the leader trials and used to investigate startle habituation during the testing session. All the trials in this session were presented in a quasi-random order (ITI = 30 s). The startle-eliciting tones had a 20 ms duration. For each animal, we calculated the mean startle magnitude in the absence (tone alone startle) and in the presence of the learned light stimulus (light + tone startle) and the percent difference between these means.

FPS analyses and interpretation. Enclosure movements (Foot Shock Reactivity) were recorded during the training session to investigate differences in sensory reactivity to the aversive foot shock. This measure provides critical information for interpreting FPS data (e.g., if the diet or treatment attenuates the acquisition of fear-potentiated startle, is this effect related to a potential analgesic effect during training so that the foot shocks fail to promote associative learning?). We assessed fear acquisition with data from the testing session. This was achieved by comparing the startle amplitude from light + tone trials (conditioned + unconditioned stimulus, CS + US) relative to tone alone trials (unconditioned stimulus, US). FPS data was reported as the change (delta) between US and CS + US (FPS = Light + Tone Startle) – (Tone Alone Startle). Conditioned fear responses that deviated from control animals were associated with potential hippocampal-related psycho-pathology. Increased potentiated startle responses (relative to controls) usually indicate heightened fear, while decreased FPS suggests deficits in fear acquisition, retention, and/or expression.

Open field test (OFT) The OFT was performed in an opaque acrylic open field maze (43.2 cm length × 43.2 cm width × 30.5 cm height). The rats were placed in the center of the field and recorded for 5 min using Ethovision XT (Noldus Information Technology). Behaviors were recorded at normal room lighting conditions (269 lux illumination). We used Ethovision to subdivide the arena into four zones, which were determined for the evaluation of inner (center) and outer arena exploration. The chamber was cleaned with 70% ethanol between trials.
Elevated plus maze (EPM)

The near-infrared (NIR)-backlit EPM apparatus (catalog #ENV-564A, MedAssociates) consisted of two opposite open arms (50.8 x 10.2 cm) and two enclosed arms (50.8 x 10.2 x 40.6 cm) that were elevated 72.4 cm above the floor. Behaviors were recorded under low light conditions (<10lx). The rat was placed on the central platform facing an open arm and allowed to explore the maze for 5 min. The apparatus was thoroughly cleaned after each test session. Behaviors were recorded via a monochrome video camera equipped with a NIR filter. The time spent on both types of arms, the number of entries and duration in both types of arms, the latency to the first entry into any of the open arms (OA), closed arms (CA) entries, frequency in the head-dipping zone, and stretch attend postures (SAPs) were determined using Ethovision XT tracking software (Noldus Information Technology). From these data, we calculated the anxiety index according to our group and others [18, 44, 53, 54]. Anxiety index = 1 - ([OA cumulative duration/total test duration] + [OA entries / total number of entries to CA – OA])/2.

Y-maze spontaneous alternation

The Y-maze apparatus was constructed of black Plexiglass with three identical arms spaced at an angle of 120 degrees (arms dimensions: 55.9 x 10.2 x 10.2 cm). Each rat was placed at the end of one of the open arms and allowed to move freely through the maze during a nine-min session. The total number of arm entries and alternations from visited to unvisited arms was recorded using a video camera, tracked using Ethovision XT (Noldus Information Technology), and scored manually by two blinded investigators. Entries occur when all four limbs are within the arm. Each arm choice was recorded, and spontaneous alternation behaviors were scored as three successive choices that include one instance of each arm (a triad). The percentage of spontaneous alternations was calculated as the total number of alternations/total arm entries – 2) x 100. This measure is considered to reflect short-term memory in rats. The alternate arm returns and same arm returns were also scored for each animal to investigate attention within spontaneous working memory. The number of total alternations was calculated as an index of locomotor activity, and rats exhibiting 0 entries were excluded from analyses. Behaviors were recorded at normal room lighting conditions (269 lux). The maze was cleaned with 70% ethanol between trials.

Magnetic resonance imaging

All fixed brain tissues underwent ex vivo high-resolution imaging using a 9.4 T Bruker Avance Imager (Bruker Biospin, Billerica, MA). All the data were collected with a 2.2-mm field of view, 0.55-mm slice thickness, and a 200 x 180 mm field of view. A 3D fast field echo with a rapid acquisition with relaxation enhancement; T2 RARE) was collected with the following parameters: repetition time (TR)/echo time (TE) = 6482 msec/49.3 msec, RARE factor of 4, for a final resolution of 110 x 111 x 550 microns. The total imaging time was 39 min.

Image acquisition and segmentation processing for microglial morphological characterization. Blinded investigators carried out image acquisition and analyses. Images of tissue sections were captured with a camera that were DAB-stained with the Iba-1 antibody were obtained using a Keyence BZ-9000 series microscope (Keyence Corporation, Osaka, Japan) in brightfield at a 40x magnification. To obtain a single high-quality full-focused composite image that showed detailed magnification of ramified processes of the cells and facilitated image segmentation, a multi-plane virtual 2-D mode with 10 images (1μm thickness) in 20μm depth of tissue section was captured using the BZ-9000 BIOREVO sectioning algorithm. Images were later combined using public domain software ImageJ (https://imagej.nih.gov/ij/). Hippocampal dorsal and ventral CA1 areas were scanned to obtain at least 3 images per region of interest per hemisphere covering a field of view area of 1.2 mm. Each acquired image was saved as a TIFF file and included at least six (6) iba-1+ cells.

Images were processed in an unbiased and systematic way to obtain a filled image. For this purpose, a series of steps were performed using ImageJ with the Fiji plugin (https://image.net/Fiji). First, a single high-quality image was obtained by merging all the single images and processing them under a minimum threshold feature to soften the background and enhance the contrast. Subsequently, the image was transformed to 8-bit grayscale and binarized to obtain a black and white image by applying a previously established threshold. To obtain a cell image consisting of continuous pixels, manual editing of each image was performed. A set threshold of pixel number addition (no more than 4 pixels) to join processes belonging to a selected cell was established and performed systematically. A 2-pixel set threshold was applied to separate ramified processes and classify them as microglial cells. Carefully performed under the view of the original z-stack images to avoid bias. The final filled shape image was saved and later analyzed with FacLab V2.5 for ImageJ [Karpen], A, FracLab for ImageJ, https://rsb.info.nih.gov/jij/plugins/FracLab/Help/Introduction.html [35] to quantify the morphological changes of microglial cells in each experimental group. Foreground pixel quantification of the filled binary images per object (cell) was done with the Box Counting (BC) feature, which counts the number of boxes containing any foreground pixels along with the successively smaller caliber grids. BC box size scale was obtained as a Power Series where the base is raised to the exponent added to it to make successive sizes. Finally, the slope for each object was the average of 12 measurements with different and random grid placements. Box Counting and Convex Hull Area measurements were exported using Excel (Microsoft, Redmond, WA, USA) for record and tabulation. Graphpad Prism version 9.0 (Graphpad Software, La Jolla, CA, USA) was used for statistical analyses. We conducted power analyses using G*Power [56]. For repeated measures two-way ANOVA (with diet type and treatment as factors and four measurements per group), post-hoc analyses revealed that three rats per group are sufficient to detect medium effect sizes (d = 0.475) with power (1 - β) set at 0.80, and a = 0.05. The statistical power (1-β) for the microglial morphometric parameters data was 0.16 for detecting a small size effect (d = 0.2), whereas the power exceeded 0.99 for the detection of large effect size (d = 0.8). This indicates that the histological experiments are adequately powered at or above a moderate size level (d = 0.4).

Neurohistology

Tissue preparation and immunohistochemistry. Before euthanasia, the animals were deeply anesthetized with an intraperitoneal overdose injection of Euthasol (150 mg/kg; Virbac, Fort Worth, TX) and sacrificed via transcardiac perfusion with 10% sucrose (isotonic at 9.25% in distilled water; prewash) and 4% paraformaldehyde (PFA; fixative) using the Perfusion Two™ Automated Pressure Perfusion System (Leica Biosystems, Buffalo Grove, IL). Following MRI, a subgroup of brains was randomly selected from each study group for histological analyses (n = 12; three rats per group). The brains were removed from the cranial vault after MRI and cleaned after each test session. Behaviors were recorded via a monochrome video camera equipped with a NIR filter. The time spent on both types of arms, the number of entries and duration in both types of arms, the latency to the first entry into any of the open arms (OA), closed arms (CA) entries, frequency in the head-dipping zone, and stretch attend postures (SAPs) were determined using Ethovision XT tracking software (Noldus Information Technology). From these data, we calculated the anxiety index according to our group and others [18, 44, 53, 54]. Anxiety index = 1 - ([OA cumulative duration/total test duration] + [OA entries / total number of entries to CA – OA])/2.
Inhibitor Cocktail (cOmplete 150 mmol/L NaCl, 1 mmol/L PMSF, 0.05% Tween-20, and a Protease inhibitor cocktail) was used to investigate the acute activation of NRG1-ErbB4 signaling pathways. The rats were euthanized with intraperitoneal administration of Euthasol (Virbac) and perfused transcardially with PBS. The brains were isolated, and corticosterone concentration was determined as the percentage bound to albumin as previously described [18]. Samples were diluted in kit assay buffer (1:3 dilution) in triplicates and run in triplicates. Triglycerides: Plasma samples were used to determine triglycerides concentration with the TG assay kit for quantification (Abcam, ab65336; Cambridge, MA, USA) according to the manufacturer’s instructions. Plasma samples were diluted in kit assay buffer (1:1 dilution) and run in triplicates. Insulin concentration was measured against a standard curve of samples ranging from 0 to 2,000 pmol/mL. TG concentration was calculated and reported as nanograms of TG per mL. FGF-21: Plasma samples were assayed for FGF-21 concentration using an ELISA kit from R&D Systems (DY377, R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions. Samples were diluted in kit assay buffer (1:2 dilution) in triplicates and concentration measured against a standard curve from 0 to 1,000 pg/mL. FGF-21 concentration was reported as pg/mL. NRG1: Hippocampal homogenates were used to determine NRG1 concentration with the Human NRG1-β ELISA (DY377, R&D Systems, Minneapolis, MN, USA). Samples were diluted in kit assay buffer (1:1 dilution) in triplicates. NRG1 concentrations were determined using the SpectraMax i3X plate reader (Molecular Devices, Sunnyvale, CA, USA). Samples were diluted against a standard curve of samples ranging from 0 to 4,000 pg/mL. NRG1 concentration was calculated and reported as nanograms of NRG1 per mL.

**Statistics**

We analyzed the data using GraphPad Prism version 9.0 (Graphpad Software, La Jolla, CA, USA). Shapiro-Wilk statistical analyses were used to determine sample distribution. The Brown–Forsythe test was used to test for the equality of group variances. Two-way analysis of variance (ANOVA) was used to examine the effect of the diet type, treatment, and interaction between factors on outcome measures. Three-way ANOVA was used to investigate the impact of the diet type, treatment, hippocampal regions, and interactions between factors on microglial morphology. Mixed-effects model analyses were used to examine the effect of the diet type, treatment, ErbB4 isofrom shape, and interactions on hippocampal ErbB4 mRNA levels. Multiple comparisons were made using Sidák’s (for one
significant main effect; within-group) or Tukey’s test (for more than one significant main effect or significant interaction effect; between-group). The ROUT method was used to determine outliers. Principal component analyses (PCA) were performed to reduce the microglia morphological descriptors’ dimensionality by using centering/scaling methods. We considered differences significant when \( p < 0.05 \). The data is shown as the mean ± standard error of the mean (SEM).

Images and figures
Illustrations were prepared using BioRender (www.Biorender.com), Omni-Graffe Pro (The Omni Group; Seattle, WA), and Prism (Graphpad Software; La Jolla, CA).

RESULTS
Early impact of macronutrient profile of diet on biometric parameters
Following the reports indicating that exogenous NRG1 improves metabolic outcomes implicated with obesity [47, 57–60], we tested whether exogenous NRG1 administration prevents/delays the onset of obesity symptoms. We postulated that exogenous NRG1 administration would attenuate the WD-induced hippocampal structural impairments and alterations in cued learning, spatial working memory, inflammatory signals, and synaptic integrity. Figure 1 details the experimental timeline and experimental groups (CDV, control diet + vehicle injections; CDN, control diet + NRG1 injections; WD, Western diet + vehicle injections; WDN, Western diet + NRG1 injections). Here, we found that adolescent rats exposed to the Western-like high-fat diet (WD) for three weeks exhibited significantly increased body weight, caloric intake, and post-prandial blood glucose concentration relative to the rats that consumed the control diet (CD) (\( p < 0.05 \); Table 1). However, three weeks of consuming the obesogenic WD was not sufficient to significantly alter critical peripheral obesity biomarkers, including leptin, insulin, triglycerides, and corticosterone (\( p > 0.05 \); Table 1). Subchronic exogenous NRG1 administration had no significant effects on the biometric parameters assessed in this study (\( p > 0.05 \); Table 1).

Exogenous NRG1 decreases trace cued fear acquisition in the adolescent rats that consume the CD but not in the rats that consumed the obesogenic WD
Recent work from our lab has focused on identifying early (mal)adaptive responses to obesogenic environments [18, 44, 48, 49, 61]. Having demonstrated that exposure to an obesogenic diet during adolescence alters the neural and behavioral substrates implicated with emotional regulation, we asked whether these impairments can be attenuated by administering neuregulin-1 (NRG1), a neurotrophic factor with potent neuroprotective and anti-inflammatory properties [38, 41, 45, 62].

Trace conditioning is thought to reflect hippocampal-dependent declarative memory [63–65]. Hippocampal lesions impair acquisition and expression of trace conditioning, while having little effect on the acquisition of amygdalar-dependent delay conditioning [66, 67]. Based on our findings reporting structural impairments in hippocampus of rats that consumed an obesogenic diet during adolescence [18], we decided to investigate the effect of the WD and exogenous NRG1 on a trace conditioning paradigm (Fig. 2A). We found no significant interaction \( F(1, 43) = 0.79, p = 0.38 \), treatment \( F(1, 43) = 0.05, p = 0.82 \), or diet \( F(1, 43) = 1.82, p = 0.19 \) effects on foot shock reactivity (Fig. 2B). Interestingly, daily NRG1 administration (5 \( \mu \)g/kg/day for 21 days between postnatal day, PND21-PND41) led to a significant reduction in fear-potentiated startle (FPS) responses at 24 h following trace cued fear conditioning. Analyses showed a significant interaction \( F(1, 43) = 4.57, p = 0.038 \) effect in FPS responses, with no significant treatment \( F(1, 43) = 2.81, p = 0.10 \) or diet \( F(1, 43) = 0.40, p = 0.53 \) (Fig. 2C). Post hoc testing revealed that this effect was unique to the animals that consumed the CD (significant differences between the CDV and CDN rats, \( p = 0.021 \)). When analyzing each separate tone intensity, we found a stimulus effect (tone alone vs. light + tone) for 90 dB \( F(1, 40) = 64.82, p < 0.0001 \), 95 dB \( F(1, 44) = 27.71, p < 0.0001 \), and 105 dB \( F(1, 43) = 37.61, p < 0.0001 \). Interestingly, only CDV rats exhibited significant differences between the stimulus type (Supplemental Fig. 2). This phenotype is consistent with previous reports from our lab proposing that obesity and the consumption of obesogenic diets saturates fear and emotional circuits [48].

WD consumption during adolescence increases indices of anxiety in the EPM
Numerous studies demonstrate that dietary obesity is associated with anxiety-related phenotypes [18, 68, 69]. To assess stress and anxiety-related responses, we employed a test battery, including the FPS, open-field test (OFT), elevated plus maze (EPM), and Y-maze. Echoing prior findings, analyses revealed a significant diet \( F(1, 43) = 7.27, p = 0.009 \), and no significant interaction \( F(1, 43) = 1.38, p = 0.25 \) or treatment \( F(1, 43) = 0.666, p = 0.80 \) effects on the EPM anxiety index (Fig. 2D). WD rats demonstrated higher anxiety indices in the EPM when compared to CDN (\( p = 0.017 \)). We used the number of closed arm entries as a proxy for locomotion in the EPM. We found no significant interaction \( F(1, 43) = 0.613, p = 0.438 \), treatment \( F(1, 43) = 0.434, p = 0.514 \), or diet \( F(1, 43) = 0.051, p = 0.822 \) effects in the number of closed arm entries (Fig. 2E). Additional OFT, EPM, and Y-maze behavioral outcomes are included in Supplemental Fig. 3.

Exogenous subchronic NRG1 reduces the hippocampal volume in adolescent rats that consume the CD but not in the rats that consume the obesogenic WD
Exogenous NRG1 confers robust anti-inflammatory [36, 37], neuroprotective [41, 45, 62], and neurogenic effects [32, 33]. In this respect, we asked whether NRG1 administration prevents hippocampal atrophy in rats that consume obesogenic diets. We examined hippocampal volumetric measurements using magnetic resonance imaging (MRI). We found a significant interaction \( F(1, 19) = 6.61, p = 0.019 \) and treatment \( F(1, 19) = 9.48, p = 0.006 \) effects on total hippocampal volume (both left and right hippocampi combined), with no diet \( F(1, 19) = 0.052, p = 0.82 \) effects (Fig. 3A, B). The rats that received prolonged NRG1 administration during early adolescence exhibited smaller hippocampi (CDV vs. CDN, \( p = 0.003 \)), an effect that was dependent on the diet type. The volumetric differences were not related to changes in total brain volume. Analyses revealed no significant interaction \( F(1, 19) = 0.14, p = 0.711 \), treatment \( F(1, 19) = 0.18, p = 0.67 \), or diet \( F(1, 19) = 0.25, p = 0.62 \) effects on total brain volume (Supplemental Fig. 4).

Hippocampal subfield segmentation revealed unique vulnerability to the experimental manipulations in the CA1 region. Analyses revealed a significant interaction \( F(1, 19) = 6.44, p = 0.020 \) and no significant treatment \( F(1, 19) = 0.11, p = 0.75 \) or diet \( F(1, 19) = 3.16, p = 0.092 \) effects (Fig. 3C, D), indicating a crossover interaction between the main factors. WDV rats had a significantly smaller CA1 volume than CDV rats (\( p = 0.035 \). Table 2 details hippocampal volumetric data and statistics. The left and right rodent hippocampi exhibit striking anatomical and functional lateralization. Similarly, it has been well-established that the human brain exhibits neuroanatomical differences between the left and right sides [70]. The human hippocampus shows normative structural asymmetries [71], reflected in differences in function and behavior between both hemispheres. Notably, studies demonstrate enhanced hippocampal asymmetry in cognitive decline, Alzheimer’s disease, and dementia [72]. In general, increased lateralization has been associated with cognitive deficits [73]. Thus, changes in the typical pattern of hippocampal asymmetry have been implicated in several
pathological states and proposed to serve as neuroanatomical markers of risk. We dissected the effects of the WD and hippocampal hemispheric lateralization (Supplemental Fig. 5C). We found significant hippocampal hemisphere lateralization [F(1, 44) = 4.71, p = 0.053] and diet type [F(1, 44) = 4.71, p = 0.043] effects, with no significant interaction [F(1, 44) = 0.053, p = 0.82] effects on hippocampal volumetrics. WD rats exhibited a reduced right hippocampal volume relative to the left in CD rats (post hoc p = 0.019). We found a significantly increased lateralization in the hippocampus of rats that consumed the WD, suggesting a novel potential neuropathological signature of early obesity (Supplemental Fig. 5C). Interestingly, the WD rats that received exogenous NRG1 did not exhibit hippocampal laterality (Supplemental Fig. 5D).

Quantitative morphometric analysis shows a diverse morphologic microglia response to an obesogenic diet and exogenous NRG1 treatment in the CA1 region of the hippocampus

Microglia are the innate immune cells of the brain. Notably, microglia have been shown to play a significant role in axonal remodeling and synaptic pruning [74], and hippocampal tissue volume [75]. Microglia are highly responsive to obesogenic diets [22, 23] and NRG1 [38, 76]. Given that microglial function is closely related to its morphology [77], we measured an array of 18 key morphometric parameters using fractal analysis (Supplemental Table 4). We focused on the CA1 hippocampal subfield based on its role on hippocampal-dependent behavior, abundant ErbB4 expression, and the observed volumetric changes and vulnerabilities of this region to several environmental insults. We performed morphological analyses in 1,981 Iba-1-positive cells (approximately 500 microglia/group). We applied Principal Component Analysis (PCA) on the morphometric parameters to trace the possible differences in microglia driving hippocampal structure and behavior changes. PCs with eigenvalues greater than 1 were used (Kaiser rule). For all groups, we had three PCs with eigenvalues greater than 1. These PCs explained more than 80% of the accumulated variance between cells (PC1: ~60%; PC2: ~20%; PC3: ~5%; Supplemental Fig. 7). The analyses allowed us to extract presumably independent (non-overlapping) factors reflecting different parameters constituting microglial shape and function in our rat model. We identified several morphometric features with variable contribution values higher than .06 (1/18; 18 total number of features). These morphometric parameters were subjected to PCA. PCA revealed distinctive morphological profiles between groups; PC1 contributed to explaining diet effects, and PC2 helped understand the differences between NRG1-treated groups (PC1 = 58, PC2 = 35%; Supplemental Fig. 8). Figure 4A shows representative microglia morphologies from hippocampal dorsal and ventral CA1 regions in each study group. Evaluation of

### Table 1. Detailed biometric parameters findings and statistics.

| Parameter | CD | WD | F | P |
|-----------|----|----|---|---|
| Body weight (g) | VEH | NRG1 | VEH | NRG1 |
|           | 146.08 ± 2.30 | 146.88 ± 2.37 | 155.37 ± 1.88 | 157.03 ± 2.30 |
|           | Interaction: F (1, 66) = 0.03 | P = 0.85 |
|           | Treatment: F (1, 66) = 0.30 | P = 0.58 |
|           | Diet: F (1, 66) = 19.20 | P < 0.0001 |
| Caloric intake (kcal/d) | 52.84 ± 0.73 | 53.09 ± 0.96 | 63.39 ± 1.59 | 66.09 ± 1.04 |
|           | Interaction: F (1, 20) = 1.18 | P = 0.30 |
|           | Treatment: F (1, 20) = 1.71 | P = 0.21 |
|           | Diet: F (1, 20) = 109.20 | P < 0.0001 |
| PBG (mg/dl) | 128.08 ± 2.77 | 132.08 ± 3.08 | 144.92 ± 4.32 | 139.75 ± 4.04 |
|           | Interaction: F (1, 44) = 1.61 | P = 0.21 |
|           | Treatment: F (1, 44) = 0.026 | P = 0.87 |
|           | Diet: F (1, 44) = 11.50 | P = 0.0015 |
| Insulin (ulU/mL) | 38.92 ± 1.85 | 41.23 ± 4.82 | 34.23 ± 3.17 | 37.47 ± 3.87 |
|           | Interaction: F (1, 18) = 0.017 | P = 0.90 |
|           | Treatment: F (1, 18) = 0.45 | P = 0.45 |
|           | Diet: F (1, 18) = 0.26 | P = 0.62 |
| Corticosterone (ng/mL) | 18.01 ± 1.66 | 19.46 ± 3.79 | 23.40 ± 3.65 | 20.94 ± 3.06 |
|           | Interaction: F (1, 18) = 0.36 | P = 0.55 |
|           | Treatment: F (1, 18) = 0.02 | P = 0.87 |
|           | Diet: F (1, 18) = 1.13 | P = 0.30 |
| Leptin (pg/mL) | 597.57 ± 57.96 | 515.13 ± 22.62 | 640.33 ± 32.80 | 532.77 ± 57.07 |
|           | Interaction: F (1, 18) = 0.075 | P = 0.79 |
|           | Treatment: F (1, 18) = 4.27 | P = 0.05 |
|           | Diet: F (1, 18) = 0.43 | P = 0.52 |
| Triglycerides (mg/DL) | 118.35 ± 0.57 | 119.84 ± 0.93 | 119.48 ± 1.33 | 114.80 ± 3.13 |
|           | Interaction: F (1, 18) = 1.94 | P = 0.18 |
|           | Treatment: F (1, 18) = 0.32 | P = 0.32 |
|           | Diet: F (1, 18) = 0.43 | P = 0.43 |
| FGF-21 (ng/mL) | 0.72 +/− 0.07 | 0.59 +/− 0.07 | 0.91 +/− 0.13 | 1.12 +/− 0.11 |
|           | Interaction: F (1, 18) = 2.75 | P = 0.11 |
|           | Treatment: F (1, 18) = 0.70 | P = 0.70 |
|           | Diet: F (1, 18) = 11.57 | P = 0.003 |

The adolescent rats that consumed the WD exhibited an increase in body weight, food consumption, circulating FGF-21 levels, and post-prandial blood glucose levels relative to animals consuming the control diet at postnatal day 41. Three weeks of consuming the WD was not sufficient to alter plasma insulin, leptin, corticosterone, and triglyceride levels in adolescent rats. Exogenous NRG-1 administration did not have a significant effect on any of the biometric parameters measured. Bold denotes significant effects following two-way ANOVA. Sample numbers: Body weight: CD + VEH, n = 17; CD + NRG1, n = 17; WD + VEH, n = 18; WD + NRG1, n = 18; Caloric intake: CD + VEH, n = 6; CD + NRG1, n = 6; WD + VEH, n = 6; WD + NRG1, n = 6. PBG: CD + VEH, n = 12; CD + NRG1, n = 12; WD + VEH, n = 12; WD + NRG1, n = 12. Insulin, CORT, Leptin, TG, and FGF21: CD + VEH, n = 5; CD + NRG1, n = 5; WD + VEH, n = 6; WD + NRG1, n = 6.
microglial density (solidity) as a measure of cell size based on area demonstrated that the WD significantly decreased microglial density in the right CA1 subfield (Fig. 4B) (ROI: $F_{(1, 8)} = 1.06, p = 0.33$; diet: $F_{(1, 8)} = 6.82, p = 0.031$; treatment: $F_{(1, 8)} = 0.01, p = 0.93$; ROI x diet: $F_{(1, 8)} = 0.82, p = 0.39$; ROI x treatment: $F_{(1, 8)} = 0.04, p = 0.84$; diet x drug: $F_{(1, 8)} = 2.17, p = 0.18$; ROI x diet x drug: $F_{(1, 8)} = 2.71, p = 0.14$). This finding suggests a less compact/more ramified microglia phenotype. Microglial lacunarity is a measure of heterogeneity that reflects sensitive changes in particular features such as soma size relative to process length [78]. We found that lacunarity was significantly increased in the right CA1 region of rats receiving the exogenous NRG1 (Fig. 4C) (ROI: $F_{(1, 8)} = 0.434, p = 0.514$; diet: $F_{(1, 8)} = 0.051, p = 0.822$). For all behaviors: sample size = 12 rats/group (before outlier testing).

Circularity is a measure of shape (soma thickness). High circularity values are associated with round sphere shapes, suggesting a

Fig. 2 Behavioral phenotypes associated with early access to an obesogenic diet and prolonged NRG1 administration. A Schematic illustration of trace FPS protocol. B Startle reactivity to the foot shocks was not affected by treatment [$F_{(1, 43)} = 0.05, p = 0.82$] or diet [$F_{(1, 43)} = 1.82, p = 0.19$]. C Fear potentiated-startle (FPS) responses were determined from trace conditioning protocol and showed a decrease in FPS in CDN rats relative to CDV (interaction: $F_{(1, 43)} = 4.57, p = 0.038$, post hoc, $p = 0.021$). D Elevated-plus maze (EPM) anxiety index was affected by the diet [$F_{(1, 43)} = 7.27, p = 0.009$]. WDN rats demonstrated higher anxiety indices in the EPM when compared to CDN ($p = 0.017$). E Number of closed arms entries in the EPM was not affected by treatment [$F_{(1, 43)} = 0.04, p = 0.84$] or diet [$F_{(1, 43)} = 0.051, p = 0.822$]. For all behaviors: sample size = 12 rats/group (before outlier testing).
more ameboid-like morphology associated with greater phagocytic activity [77]. NRG1 administration reduced circularity (induced irregular shape) in the right CA1 region (Fig. 4C) (ROI: \( F_{1,8} = 3.71, p < 0.011 \)); ROI x diet: \( F_{1,8} = 5.52, p = 0.047 \)); ROI x treatment: \( F_{1,8} = 13.04, p = 0.007 \)); diet x drug: \( F_{1,8} = 3.56, p = 0.10 \)); ROI x diet x drug: \( F_{1,8} = 0.40, p = 0.85 \)) and CV from all Raddi from Circle (ROI: \( F_{1,8} = 0.52, p = 0.48 \)) and CV from all Raddi from Circle (ROI: \( F_{1,8} = 0.52, p = 0.48 \)). Analyses revealed significant interaction effects for Max/Min Raddi (ROI: \( F_{1,8} = 3.71, p < 0.011 \)); ROI x diet: \( F_{1,8} = 5.52, p = 0.047 \)); ROI x treatment: \( F_{1,8} = 13.04, p = 0.007 \)); diet x drug: \( F_{1,8} = 3.56, p = 0.10 \)); ROI x diet x drug: \( F_{1,8} = 0.40, p = 0.85 \)) and CV from all Raddi from Circle's Center (ROI: \( F_{1,8} = 2.16, p = 0.18 \)); diet: \( F_{1,8} = 0.03, p = 0.87 \)); treatment: \( F_{1,8} = 0.90, p < 0.37 \)); ROI x diet: \( F_{1,8} = 3.57, p = 0.10 \); ROI x treatment: \( F_{1,8} = 5.95, p = 0.041 \)); diet x drug: \( F_{1,8} = 1.53, p = 0.25 \)); ROI x diet x drug: \( F_{1,8} = 1.16, p = 0.31 \)) in the right CA1 hippocampal subfield. Complete details regarding microglial morphology descriptors definitions can be found in Supplemental Table 4. Detailed microglial parameter values were reported as mean ± SEM for each group (Supplemental Table 5).

**WD consumption increases cytokine concentrations while exogenous NRG1 administration decreases selective cytokine concentrations in the rat hippocampus**

Obesity is associated with a robust neuroinflammatory state via increased inflammatory mediators. Our data revealing diet-induced changes in microglial morphology prompted us to examine hippocampal cytokine concentrations. Using a bead-based flow cytometry immunoassay, we found that the WD exerted a precise cytokine regulation (Fig. 5). The rats that consumed the WD exhibited a significant increase in pro-inflammatory cytokines in the hippocampus: IL1-α (\( p = 0.010 \)), TNF-α (\( p = 0.006 \)), and IL-6 (\( p = 0.019 \)). Interestingly, the anti-inflammatory cytokine, IL-10, was also significantly increased in WD rats (\( p = 0.027 \)). Opposite to the main dietary effects in increasing hippocampal cytokine concentrations, exogenous NRG1 administration significantly reduced IL-33 (\( p = 0.041 \)), GM-CSF (\( p = 0.021 \)), CCL-2 (\( p = 0.037 \)), and IFN-γ (\( p = 0.031 \)), confirming the potent immunomodulatory effects of NRG1 [37, 38].

Notably, WD and NRG1 influenced the concentrations of several peripheral cytokines and inflammatory mediators (Supplemental Fig. 9). Exogenous NRG1 decreased IL-10 plasma concentration (diet: \( F_{1,16} = 2.38, p = 0.14 \)); treatment \( F_{1,16} = 15.71, p = 0.0011 \)); interaction: \( F_{1,16} = 0.17, p = 0.69 \)) (Supplemental Fig. 9A). We found that exogenous NRG1 administration reduced IL-17A concentration in plasma (diet: \( F_{1,15} = 0.57, p = 0.46 \)); treatment \( F_{1,15} = 7.18, p = 0.017 \)); interaction: \( F_{1,15} = 2.02, p = 0.18 \)) (Supplemental Figure 9B). Interestingly, we found that while the obesogenic WD increased the concentration of CXCL1, exogenous NRG1 elicited a marked reduction in the levels of this chemokine (diet: \( F_{1,16} = 13.63, p = 0.0020 \)); treatment \( F_{1,16} = 23.80, p = 0.00020 \)); interaction: \( F_{1,16} = 0.52, p = 0.48 \))...
(Supplemental Fig. 9C). We found that the rats that consumed the WD exhibited reduced IL-33 concentration in plasma (diet: $F_{(1, 100)} = 8.67, p = 0.0095$, treatment: $F_{(1, 100)} = 2.70, p = 0.12$; interaction: $F_{(1, 100)} = 0.12, p = 0.74$) (Supplemental Fig. 9D). Supplemental Table 3 includes the results and statistics of the hippocampal cytokines tested in this study.

**WD consumption and exogenous NRG1 synergize to enhance hippocampal ErbB4 phosphorylation and sheddase protein levels**

ErbB4 is the predominant ErbB family member expressed in microglia [79] and has the highest affinity for NRGs, and was reported to bind to the NRG-1β isoform administered in this study avidly [80, 81]. ErbB3 binds NRG-1 but has very little kinase activity [82] and therefore must heterodimerize with other ErbB family members to activate signaling cascades. On the other hand, ErbB4 also differs from ErbB3 in that, when activated by NRGs, it is a highly active tyrosine kinase that can form functional receptor complexes by hetero- or homodimerization [83]. We and others have contributed to identifying the effects of NRG1-ErbB4 signaling on microglia/inflammation [37, 38, 79, 84–86]. Having established that NRG1-ErbB4 regulates inflammatory signals and microglia function, we focused on this family member [79, 87]. We found that the obesogenic WD decreased total ErbB4 protein levels in the hippocampus (Fig. 6A). Analyses revealed a significant effect of treatment [$F_{(1, 16)} = 7.97, p = 0.012$] and diet [$F_{(1, 16)} = 7.34, p = 0.016$] effect, while showing no significant interaction [$F_{(1, 16)} = 0.96, p = 0.34$] effects on ErbB4 protein levels. Post hoc testing revealed that WD rats exhibited significantly lower ErbB4 protein levels when compared to CD rats ($p = 0.009$). Notably, exogenous NRG1 administration caused hyperphosphorylation of hippocampal ErbB4 (Fig. 6B). Analyses revealed a significant treatment [$F_{(1, 100)} = 5.82, p = 0.027$] and diet [$F_{(1, 100)} = 7.36, p = 0.014$] effect, while no significant interaction [$F_{(1, 100)} = 0.13, p = 0.73$] effects on protein levels. ErbB4 hyperphosphorylation was particularly evident in WDN rats relative to the CDV group ($p =$

---

Table 2. A Detailed right hippocampal subfield volumetrics and statistics. B Detailed left hippocampal subfield volumetrics and statistics.

| Source of Variation | CD VEH | CD NRG | WD VEH | WD NRG | CD VEH | CD NRG | WD VEH | WD NRG |
|---------------------|--------|--------|--------|--------|--------|--------|--------|--------|
| Region              | Mean   | SEM    | Mean   | SEM    | Mean   | SEM    | Mean   | SEM    |
| Diet                |        |        |        |        |        |        |        |        |
| Drug                |        |        |        |        |        |        |        |        |
| Region x Diet       |        |        |        |        |        |        |        |        |
| Region x Drug       |        |        |        |        |        |        |        |        |
| Diet x Drug         |        |        |        |        |        |        |        |        |
| Region x Diet x Drug|        |        |        |        |        |        |        |        |
| Subject SS, 32.29   |        |        |        |        |        |        |        |        |

Bold denotes significant effects following three-way ANOVA and post hoc comparisons between CD + VEH and CD + NRG1. Subject refers to the differences among subjects (variation source expressed as Sum of Squares, SS). Sample numbers: CD + VEH, n = 6; CD + NRG1, n = 6; WD + VEH, n = 6; WD + NRG1, n = 6. Bold denotes significant effects following three-way ANOVA and post hoc comparisons between CD + VEH and CD + NRG1. Subject refers to the differences among subjects (variation source expressed as Sum of Squares, SS). Sample numbers: CD + VEH, n = 6; CD + NRG1, n = 6; WD + VEH, n = 6; WD + NRG1, n = 6.
0.012). Immunohistological evaluation demonstrated pErbB4 expression in hippocampal Cd11b/c cells from rats treated with exogenous NRG1 (Supplemental Fig. 6A). Supporting the expression and roles for NRG1-ErbB4 signaling in microglia cell function [38, 79, 85, 87].

NRG1 and ErbB4 (trans)activation via proteolytic processing is achieved by the shedding protease TNF-α-Converting Enzyme (TACE, also known as ADAM17) [88–90]. We found that the WD increased TACE/ADAM17 protein levels in the hippocampus (Fig. 6C). We identified a significant treatment $F_{(1, 17)} = 8.93, p = 0.008$
Obesogenic diet and exogenous NRG1 injections alter microglial shape in the hippocampus. Full-focused composite 40x images were acquired from twelve (12) rats. Hippocampal dorsal and ventral CA1 areas were scanned to obtain at least three (3) images per region of interest per hemisphere covering a field of view area of 1.2 mm. Each acquired image was saved as a TIFF file and included at least six (6) Iba-1+ cells. A Representative microglia morphologies from hippocampal dorsal and ventral CA1 regions in each study group. B Diet effects on hippocampal microglia morphology: evaluation of microglial density as a measure of cell size based on area demonstrated that the WD significantly decreased microglial density in the right CA1 subfield (diet: \( F_{1,6} = 6.82, p < 0.031 \)). Lacunarity was significantly increased in the right CA1 subfield of rats that consumed an obesogenic WD (diet: \( F_{1,8} = 12.09, p < 0.008 \)). C Exogenous NRG1 effects on hippocampal microglia morphology: the span ratio was significantly increased in the right CA1 region of rats receiving the exogenous NRG1 (treatment: \( F_{1,8} = 15.43, p < 0.004 \)). NRG1 administration reduced circularity in the right CA1 region (treatment: \( F_{1,8} = 9.67, p < 0.014 \)). Sample size = approximately 500 microglia per group; 3 rats/group.

and diet \( F_{1,7} = 11.03, p = 0.004 \) effect, while no significant interaction \( F_{1,7} = 0.099, p = 0.76 \) effects on protein levels. In agreement with the hippocampal pErkB4 protein levels results, we found that WDN rats showed increased TACE/ADAM17 protein levels when compared to CDV rats (\( p = 0.001 \)).

We measured PSD-95, Akt, and Erk protein levels to investigate the impact of the WD and NRG1 on molecular pathways implicated in ErbB4 signaling. NRG1 administration showed a significant decrease for a postsynaptic regulator of ErbB4 dimerization, PSD-95 (WD vs. VEH: \( p = 0.027 \), and CDV: \( p = 0.019 \), Fig. 6D). Analyses revealed a significant treatment \( F_{1,18} = 4.47, p = 0.048 \), and no significant diet \( F_{1,16} = 2.83, p = 0.11 \) or interaction \( F_{1,18} = 1.02, p = 0.33 \) effects on PSD-95 protein levels. Raw Western blot images are included in Supplemental Figs. 10–13. Analyses for pAkt (normalized to total Akt) showed no significant interaction \( F_{1,7} = 0.71, p = 0.41 \), treatment \( F_{1,7} = 0.16, p = 0.69 \), or diet \( F_{1,7} = 2.80, p = 0.12 \) effects on protein levels (Supplemental Fig. 14A). Similarly, analyses for pErk1/2 (normalized to total Erk) showed no significant interaction \( F_{1,18} = 1.13, p = 0.30 \), treatment \( F_{1,18} = 0.88, p = 0.36 \), or diet \( F_{1,18} = 0.35, p = 0.56 \) effects on protein levels (Supplemental Fig. 14B).

TACE/ADAM17 protein levels correlate with hippocampal pErkB4
We examined potential mechanisms explaining the reduced ErbB4 expression and increased pErkB4 protein levels in the rats that consumed the obesogenic WD. Twenty-one (21) days of consuming the WD and receiving NRG1 administration was not sufficient to significantly alter NRG1 protein levels in the hippocampus (Supplemental Fig. 15). Analyses showed no significant interaction \( F_{1,18} = 0.14, p = 0.72 \), treatment \( F_{1,18} = 0.031, p = 0.86 \), or diet \( F_{1,18} = 0.38, p = 0.54 \) effects on hippocampal NRG1 protein levels, as measured by ELISA.

Four (4) structurally and functionally distinct ErbB4 isofoms have been identified. One pair of isofoms differs within their extracellular juxtamembrane domains. These juxtamembrane ErbB4 isofoms are either susceptible (JMa) or resistant (JMb) to proteolytic processing that releases a soluble receptor ectodomain. We used qRT-PCR to examine the effect of the WD and NRG1 on the regulation of hippocampal ErbB4 isofoms. We found lower JMa mRNA levels in the WD rats (relative to CD rats) and higher JMb in the rats that received the exogenous NRG1 (relative to VEH) (Supplemental Fig. 16). Notably, mixed-effects model
analyses revealed a significant interaction between isoform x diet \(F(3, 57) = 3.13, p = 0.033\) and isoform x treatment \(F(3, 57) = 2.79, p = 0.049\).

In summary, our data demonstrate that WD consumption reduces hippocampal ErbB4 protein levels while increasing its phosphorylation. TACE/ADAM17 activities may lead to reduced ErbB4 and also to ErbB4 transactivation [90]. We performed Pearson’s correlation analyses to test this idea. ADAM17 hippocampal protein levels showed a robust significant correlation with ErbB4 protein levels \((r = -0.59, p = 0.007; \text{Fig. 7A})\). ADAM17
protein levels were positively associated with hippocampal pErB4 protein levels ($r = 0.53, p = 0.012$; Fig. 7B). A significant negative relationship was found between ADAM17 protein levels and PSD-95 protein levels in the hippocampus ($r = -0.54, p = 0.012$; Fig. 7C). Figure 8 describes our working model. We propose that obesogenic diets rich in saturated fatty acids promote TACE/ADAM17-mediated proteolytic cleavage of critical neurodevelopmental and neuroinflammatory processes, and consequently, lead to hippocampal synaptic/structural impairments implicated with anxiety disorders.

**DISCUSSION**

We designed the experiments to verify the thesis that exogenous NRG1 protects against obesity-related neuroinflammation, anxiety, and altered morphology of the rat hippocampus. We showed that exogenous NRG1 administration abolished the obesity-related overproduction of inflammatory cytokines in the hippocampus. NRG1 administration affected anxiety and hippocampal morphology independently to an obese-associated phenotype.

Obesity and the dietary intake of saturated fats and simple sugars have emerged as risk factors for the development of anxiety and stress-related disorders [2–6]. Consistent with studies in humans, we reported that the consumption of obesogenic diets in rats: (1) reduces hippocampal volume [18], (2) impairs the maturation of the corticolumbic fear circuits [48], (3) enhances behavioral vulnerabilities to psychosocial stress [18, 48, 91], (4) results in profound fear learning and extinction learning deficits [48, 91], even in the absence of an obesogenic phenotype [92], and (5) leads to alterations in biomarkers implicated in inflammatory responses [49]. As valuable as these earlier findings have in constructing a conceptual framework for the impact of obesogenic environments on hippocampal maturation, our current understanding is primarily based on molecular, cellular, and behavioral analyses of obese versus control animals at the end of dietary manipulations (when rats are considered obese; in our model, approximately at eight weeks after WD exposure). Less is known about the early molecular events and mechanisms contributing to hippocampal structural and functional impairments in obesity, and thus was the focus of this study.

Here, we sought to determine whether exogenous NRG1 administration prevents early hippocampal abnormalities in adolescent rats exposed to an obesogenic Western diet (WD). We report that the obesogenic WD induces anxiety-like behaviors before the onset of obesity-related changes in metabolism. We also report unique anatomical vulnerabilities to the obesogenic WD, particularly in the CA1 subfield of the hippocampus. These behavioral and anatomical alterations were associated with changes in microglial morphology, unique neuroinflammatory cytokine profiles, ErbB4 hyperphosphorylation, and increased TACE/ADAM17 protein levels. Interestingly, the obesogenic WD-driven cytokine profiles were partly ameliorated in rats receiving exogenous NRG1. Exogenous NRG1 administration during adolescence altered hippocampal structure, microglia morphology, and the concentration of several inflammatory mediators. The main findings of the study are summarized in Supplemental Fig. 1.

The consumption of an obesogenic diet during early adolescence promotes neuroinflammation and anxiety-like behaviors while increasing hemispheric differences in hippocampal volumes

Using a behavioral battery of tasks dependent on optimal hippocampal function, we demonstrated that three weeks on an obesogenic WD increased anxiety-like indices in the elevated plus maze in adolescent rats. The rats exposed to the obesogenic WD also exhibited increased locomotor activity (exploratory behavior) in the open field test. Trace fear conditioning and spatial working memory tasks were not affected in the rats that consumed the WD. An interesting finding of this study is that WD rats exhibited attenuated FPS reactivity during high-intensity tone trials (Supplemental Fig. 2). This failure to show enhanced startle reactivity during high-intensity tone trials could not be attributed to blunted reactivity to the aversive foot shocks or acoustic stimuli. Interestingly, this phenotype is strikingly consistent with our prior work on adolescent dietary obesity and traumatic stress [48]. We interpreted these observations as saturation of the fear circuitry, which is supported by studies by Walker and Davis [93].

Prior work from our group identified unique hippocampal structural vulnerabilities to obesogenic environments [18]. We reported that, during adolescence, the ventral hippocampus (vHPC) is highly susceptible to the impact of an obesogenic diet. In contrast, the dorsal hippocampus (dHPC) appears to be more vulnerable to stress in a psychogenic stress rat model [18]. Such selective vulnerability within the adolescent hippocampus implies region- and cell-selective molecular heterogeneity that remains poorly understood. Here, MRI-based volumetrics demonstrated that three weeks on the obesogenic diet was sufficient to enhance hippocampal lateralization, which is a structural signature associated with impaired cognition in humans [73]. Given that vHPC but not the dHPC CA1 fields project directly to hypothalamic nuclei critical in stress regulation, anxiety, and food intake control [16, 17, 94], we proposed that early structural alterations to this circuit represent a risk factor for both obesity-induced anxiety and anxiety-induced obesity. Animal studies have highlighted the role of the vHPC in the acquisition of mature brain physiology through the refinement of GABAergic circuits during adolescence.

GABAergic interneurons may represent a crucial cellular target in obesity. The calcium-binding protein parvalbumin (PV) is considered a core molecular marker for GABAergic interneurons. Interestingly, PV-positive cells circumscribed to the ventral region of the vHPC undergo protracted development and increase in numbers during mid-adolescence in rats [95]. Notably, these cells express high levels of ErbB4 [96], regulate spine formation [97], and are highly susceptible to environmental stressors due to their high metabolic activity [96]. Elegant studies by Reichelt et al., demonstrated that male mice that consume an obesogenic diet had reduced PV-positive cell numbers in the CA1 of the hippocampus [99]. These changes were associated with alterations in microglia morphology (less ramified, more ameboid) [99]. Notably, these effects were observed during adolescence and not during adulthood [99]. Collectively, these findings direct attention to the right vHPC CA1 as a relevant region in adolescent obesity and its related complications.
Hyper-NRG1 conditions reduce hippocampal volume and attenuate trace fear conditioning and, in a diet-type dependent manner

Neuregulin-1 (NRG1) and its ErbB receptor tyrosine kinases are expressed in the developing nervous system and in the adult brain. ErbB4 is likely to be the primary mediator of NRG1 functions in the brain, and it is mainly expressed in hippocampal GABAergic interneurons, where it is enriched at postsynaptic terminals [100]. NRG1 signaling participates in several critical neurodevelopmental processes and is implicated in nerve cell differentiation and synapse formation, radial glia formation and neuronal migration, axon navigation, and neurite outgrowth [101]. Perturbations in NRG1/ErbB4 function have been associated with various neuropsychiatric disorders [101], resilience to stress [31], and obesity/metabolic syndrome [47, 57, 102, 103]. Emerging evidence suggests that ErbB4 may also be important in the pathogenesis of obesity in humans [24, 103].

The NRG1 isoform β that was administered in this study is more highly expressed in the brain and has the highest affinity for ErbB receptors [80, 81]. In the hippocampus, pro-NRG-1β is abundant in presynaptic CA3 pyramidal neurons, and it is cleaved and released in an activity-dependent manner [104-106]. Although exogenous NRG1 has a relatively short life in plasma, we and others have shown that NRG1 crosses the BBB [46, 107, 108]. A key finding of this study is that prolonged NRG1 administration during early adolescence reduced hippocampal volume in the rats that consumed the CD. The effects of NRG1 on hippocampal structure were associated with reduced ErbB4/PSD-95 protein levels in the hippocampus. ErbB4 is localized at the postsynaptic density (PSD) of glutamatergic synapses, presumably by interacting with the PSD protein PSD-95 [109-112]. PSD-95 expression promotes the maturation of excitatory (glutamatergic) synapses, increasing the number and size of dendritic spines [113]. Loss of synaptic connections is likely to have consequences for hippocampal network organization and volume [114, 115]. Interestingly, manipulating microglial activation with minocycline restores PSD-95 protein levels in the hippocampus of aged mice [116], which validates the role of these cells in regulating synaptic densities and hippocampal volume. It is also probable that the exogenous NRG1 acted peripherally to impact the brain. We have demonstrated that NRG1 influences several peripheral cytokines and inflammatory mediators (Supplemental Figure 9) [36]. Recent studies demonstrate that the fibroblast growth factor-21 (FGF21), an hepatokine, is partly responsible for the beneficial actions of an exogenously administered NRG1 fusion protein on obesity-related metabolic outcomes [47]. Here, WD rats exhibited higher FGF21 levels, particularly those receiving the exogenous NRG1 injections (Table 1), which supports the FGF-21-resistant state observed in

**Fig. 7** TACE/ADAM17 hippocampal protein levels are associated with ErbB4 activities. A ADAM17 hippocampal protein levels negatively correlates with ErbB4 protein levels ($r = -0.59, p = 0.007$). B ADAM17 protein levels positively correlates with hippocampal pErbB4 protein levels ($r = 0.53, p = 0.012$). C ADAM17 protein levels negatively correlates with PSD-95 protein levels in the hippocampus ($r = -0.54, p = 0.012$). Sample size = 5–6 rats/group. Sample numbers: CD + VEH, $n = 6$; CD + NRG1, $n = 6$; WD + VEH, $n = 6$; WD + NRG1, $n = 6$. 

**Translational Psychiatry (2022) 12:83**
obese humans [117]. Given that hippocampal microglia respond to FGF21 [118], exogenous NRG1 may alter microglial morphology and inflammatory mediators via FGF21 regulation. NRG1-ErbB4 dysregulation may result in altered inhibitory/excitatory (I/E) balance in hippocampal circuits and, thus, a limited ability to form and retain fear memories [119–121]. Together, it is clear that NRG1 is a potent modulator of hippocampal volume and cognition.

Short-term exposure to an obesogenic WD and hyper-NRG1 conditions alter microglial morphology

Microglia cells, the resident immune cells in the brain, are responsible for maintaining a dynamic balance between anti-inflammatory and pro-inflammatory mediators. Microglia cells play a significant role in the behavioral outcomes associated with obesity [23, 122, 123]. However, the underlying molecular mechanisms regulating the microglia-dependent inflammatory balance remain poorly understood. Microglia express ErbB2, 3, and 4 receptors [84, 87, 124] and are highly responsive to NRG1 [38, 76]. Yet, the function of this signaling pathway within microglia is poorly understood. While it is very likely that the observed NRG1 effects are related to changes in local microcircuits (PV + interneurons exhibit high ErbB4 expression) [96], this study provides additional support to the notion that NRG1-ErbB4 signaling regulates microglial morphology and inflammatory mediators [38, 84–86, 125]. In our model, density, lacunarity, span ratio, and circularity were sensitive morphological indicators of WD- and NRG1-induced microglia changes. Evaluation of density (solidity) demonstrated that short-term exposure to an obesogenic WD significantly decreased this parameter in the right CA1 subfield. This decrease in density indicates a less compact phenotype. Microglial lacunarity reflects cellular heterogeneity and identifies sensitive changes in specific features (e.g., soma size relative to the length of processes) [78]. We found increased lacunarity in the right CA1 of WD rats, suggesting higher cellular complexity and perhaps a hyper-ramified transitional state relative to controls [126]. Together, the WD induced a morphotype usually accompanied by synaptic protein engulfment and remodeling [126–128]. Exogenous NRG1 administration resulted in a high span ratio (form factor) in the right CA1 region. The span ratio describes the cell shape and is based on the ratio of length and height of the Convex Hull area occupied by the cell [77]. The higher the span ratio, the more negligible area difference between the soma and processes, suggesting a more de-ramified/rod-like shape [129]. Interestingly, this phenotype is highly proliferative [130], which supports NRG1 effects on microglia [84].

Microglial...
circularity was also sensitive to exogenous NRG1. Circularity is a measure of shape and size and was found to be reduced in NRG1-treated rats. Low circularity values are associated with lower roundness (sphere-like) shapes and are inversely associated with the span ratio [129]. Taken together, adolescent exposure to an obesogenic WD and exogenous NRG1 influenced selective morphological metrics related to complexity, ramification, and shape. Our findings support the highly dynamic changes associated with microglia activation and synaptic remodeling [77, 126, 127].

The interplay between neurotrophic and neuroinflammatory mediators in obesity

Genetic studies have demonstrated strong associations between single-nucleotide polymorphisms in the ErbB4 gene and obesity [24, 103]. Notably, while ErbB4 deletion predisposes mice to metabolic alterations implicated in obesity, NRG1 administration is known to improve metabolic health in obese mice by lowering blood glucose, improving insulin sensitivity, and reducing caloric intake [47, 57, 102]. Recent studies have reported a sex-specific interplay between NRG1 signaling and high-fat diet (HFD) consumption in mice [131–133]. Consistent with a growing list of studies demonstrating the potential involvement of NRG-ErbB signaling in obesity [24, 47, 57, 102, 103, 134], we found several significant interactions between the obesogenic diet and exogenous NRG1. We present new evidence demonstrating that exogenous NRG1 effects on the fear-potentiated startle, total signifcant interactions between the obesogenic diet and exogenous NRG1. We present new evidence demonstrating that exogenous NRG1 effects on the fear-potentiated startle, total hippocampal and CA1 subfield volume, and selective hippocampal cytokines (TNF-α, IL-10, IL-6) are influenced by short-term access to an obesogenic diet. These findings are in agreement with evidence supporting that neuroinflammation and palmitate can disrupt NRG1-ErbB signaling [39, 135]. Interestingly, exogenous NRG1 synergized with the obesogenic diet to enhance ErbB4 phosphorylation and its proteolytic processing [90]. ErbB4 proteolytic cleavage is mediated by the tumor necrosis factor-α-converting enzyme (TACE) / a Disintegrin And Metalloproteinase 17 (ADAM17)-dependent ectodomain shedding in a protein kinase C (PKC)-dependent manner. Here, we present data suggesting a role for TACE/ADAM17 on ErbB4 activities and synaptic integrity. Together with our previous studies, the findings reported here indicate that exposure to an obesogenic diet during adolescence selectively affects hippocampal structure and specific cognitive domains. Our investigations support that early adolescence is a critical window during which obesogenic diets may exert anxiogenic effects.

Limitations

Our results demonstrate significant alterations in neurotrophic and neuroinflammatory signals in adolescent rats that consume an obesogenic diet enriched in saturated fats and simple sugars. However, the temporal window in which these effects take place was not established. The spatiotemporal expression of hippocampal ErbB4 and associated cytokine profiles must be determined to clarify a mechanism better. The impact of daily i.p. injections may confound the interpretation of the study. While this represents one of the best approaches to achieve therapeutic NRG1 levels in circulation (NRG1 has a short half-life), it is possible that the subchronic daily injection regime affected some endpoint measures. Furthermore, it is not clear from our results whether the NRG1 effects on hippocampal structure and behaviors are mediated by microglia, a change in the extracellular milieu via intermediate factors, or in response to intense neuronal activities induced by ErbB4 phosphorylation. Future studies should be carried out to disentangle the relative contribution of neurons and microglia to the observed effects. The use of inhibitors (e.g., AG1478) or fusion proteins (e.g., ecto-ErbB4) needs to be considered to dissect mechanisms and determine causality. Selecting appropriate single protein loading controls continues to represent a challenge for the Western blot technique, particularly for analyzing low-expressing protein targets in rodent models of diet-induced obesity. While the use of β-actin as loading control has been shown to be affected in mice models of obesity [136], the conditions of this study are different (e.g., diet composition, duration of exposure, rodent model, and age). However, in light of prior evidence, readers must exercise caution when interpreting molecular results normalized to most common housekeeping genes/proteins. Interpretation of the study may also be confounded by the effect of multiple behavioral tests on the same animal. Future experiments are required to dissociate the chronic vs. acute response to the NRG1 injection on molecular targets. Additionally, the study should be replicated in female rats and other rodent strains.

CONCLUSION

Current pathophysiological models explaining how early exposure to obesogenic diets alters brain and behavior have focused on neurodevelopmental or immunological mechanisms. We report a novel interaction between these factors in the maturing hippocampus. Our results indicate that a short-term (21 days) dietary challenge with an obesogenic WD during the critical neurodevelopmental stage of adolescence disrupts ErbB4 activities in the hippocampus. Most importantly, we continue to provide evidence that WD consumption during adolescence leads to neuroanatomical, inflammatory, and molecular alterations related to depression, anxiety disorders, and cognitive impairments in humans. While extrapolating our data must be made carefully, our results indicate that TACE/ADAM17-ErbB4 hyperfunction may contribute to abnormal hippocampal structural and cognitive vulnerabilities in individuals who consume obesogenic diets.

REFERENCES

1. Moreno LA, Rodriguez G, Fleta J, Bueno-Lozano M, Lazar A, Bueno G. Trends of dietary habits in adolescents. Crit Rev Food Sci. 2010;50:106–12.
2. Scott KM, McGee MA, Wells JE, Browne MAO. Obesity and mental disorders in the adult general population. J Psychosom Res. 2008;64:97–105.
3. Salari-Moghaddam A, Keshtei AH, Afshar H, Esmaillzadeh A, Adibi P. Association between dietary inflammatory index and psychological profile in adults. Clin Nutr. 2018. https://doi.org/10.1016/j.clnu.2018.10.015.
4. Simon GE, Korff MV, Saunders K, Miglioretti DL, Crane PK, Belle GV, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiat. 2006;63:824–30.
5. Opel N, Thalamuthu A, Milaneschi Y, Grotegord D, Flint C, Leenings R, et al. Brain structural abnormalities in obesity: relation to age, genetic risk, and common psychiatric disorders. Mol Psychiat. 2021;26:4839–52.
6. Bornstein SR, Schuppanenes A, Wong M-L, Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Mol Psychiat. 2006;11:892–902.
7. Lopresti AL, Drummond PD. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;45:92–99.
8. Hruby A, Lieberman BR, Smith TJ. Symptoms of depression, anxiety, and post-traumatic stress disorder and their relationship to health-related behaviors in over 12,000 US military personnel: bi-directional associations. J Affect Disord. 2021;283:84–93.
9. Jacka FN, Cherbuin N, Anstey KJ, Sachdev P, Butterworth P, Wellburn P. Western diet is associated with a smaller hippocampus: a longitudinal investigation. Bmc Med. 2015;283:84–93.
10. Mestre ZL, Bischoff-Grethe A, Eichen DM, Wierenga CE, Strong D, Boutelle KN. Hippocampal atrophy and altered brain responses to pleasant tastes among obese compared with healthy weight children. Int J Obes. 2017;41:1496–502.
11. Cherbuin N, Sargent-Cox K, Fraser M, Sachdev P, Anstey KJ. Being overweight is associated with hippocampal atrophy: the PATH Through Life Study. Int J Obes. 2015;39:1509–14.
12. Raji CA, Ho AJ, Parikhshak NN, Becker JT, Lopez OL, Kuller LH, et al. Brain structure and obesity. Hum Brain Mapp. 2010;31:533–64.
13. Liu CM, Kanosi SE. Homeostatic and non-homeostatic controls of feeding behavior: distinct vs. common neural systems. Physiol Behav. 2018;193:223–31.

Translational Psychiatry (2022) 12:83
37. Li Y, Lein PJ, Ford GD, Liu C, Stovall KC, White TE, et al. Neuregulin-1 inhibits
35. Jalilzad M, Jafari A, Babaei P. Neuregulin1
34. Ryu J, Hong B-H, Kim Y-J, Yang E-J, Choi M, Kim H, et al. Neuregulin-1 attenuates
29. Mahar I, Labonte B, Yogendran S, Isingrini E, Perret L, Davoli MA, et al. Disrupted
28. Kwon O-B, Paredes D, Gonzalez CM, Neddens J, Hernandez L, Vullhorst D, et al.
25. Mei L, Xiong W-C. Neuregulin 1 in neural development, synaptic plasticity and
23. Cope EC, LaMarca EA, Monari PK, Olson LB, Martinez S, Zych AD, et al. Microglia
21. Asch RH, Holmes SE, Jastreboff AM, Potenza MN, Baldassarri SR, Carson RE. et al.
20. Taylor ZB, Stevenson RJ, Ehrenfeld L, Francis HM. The impact of saturated fat,
17. Jimenez JC, Su K, Goldberg AR, Luna VM, Biane JS, Ordek G, et al. Anxiety cells in
19. Bauer CCC, Moreno B, González-Santos L, Concha L, Barquera S, Barrios FA. Child
16. Li Y, Lein PJ, Liu C, Bruun DA, Giuliani C, Ford GD, et al. Neuregulin-1 is neuro-
protective in a rat model of organophosphate-induced delayed neuronal injury.
Toxicol Appl Pharm. 2012;262:194–204.
15. Vega-Torres JD, Azadian M, Rios-Orsini RA, Reyes-Rivera AL, Ontiveros-Angel P,
Figueroa JD. Adolescence vulnerability to heightened emotional reactivity and anxiety
after brief exposure to an obesogenic diet. Front Neurosci-switz. 2020:14:562.
14. Caillaud K, Boisseau N, Ennequin G, Chavanelle V, Etienne M, Li X, et al. Neur-
38. Gao R, Ji M-H, Gao D-P, Yang R-H, Zhang S-G, Yang J-L, et al. Neuroinflammation-
39. Gao R, Ji M-H, Gao D-P, Yang R-H, Zhang S-G, Yang J-L, et al. Neuroinflammation-
induced downregulation of hippocampal neuregulin 1-ErB4B signaling in the
parvalbumin interneurons might contribute to cognitive impairment in a mouse model of
sepsis-associated encephalopathy. Inflammation. 2016;40:1–14.
30. Tan G-H, Liu Y-Y, Hu X-L, Yin D-M, Mei L, Xiong Z-Q. Neuregulin 1 represses
limbic epileptogenesis through ErB4B in parvalbumin-expressing interneurons.
31. Guan Y-F, Wu C-Y, Fang Y-Y, Zeng Y-N, Luo Z-Y, Li S-J, et al. Neuregulin-1 protects
against ischemic brain injury via ErB4 receptors by increasing GABAergic transmission.
Neuroscience. 2015;307:151–9.
32. Zhang H, Zhang L, Zhou D, He X, Wang D, Pan H, et al. Ablating ErB4 in PV
neurons attenuates synaptic and cognitive deficits in an animal model of Alz-
heimer’s disease. Neuron. 2016;518:197–210.
33. du Sert NP, Hurst V, Alhwhalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE
guidelines 2.0: updated guidelines for reporting animal research. Plos Biol. 2020;18:e000410.
34. Vega-Torres JD, Azadian M, Rios-Orsini RA, Reyes-Rivera AL, Ontiveros-Angel P,
Figueroa JD. Adolescence vulnerability to heightened emotional reactivity and anxiety
after brief exposure to an obesogenic diet. Front Neurosci-switz. 2020:14:562.
1. Neuropharmacology. 2008;61:1413–25.
2. Ruiz G, Bernal-Morales B. Myristic acid produces anxiolytic-like effects in wistar rats.
Neurosci. 2018;38:4889–904.
3. Locke AE, Kahali B, Bermdt SJ, Justice AE, Pers TH, Day FR, et al. Genetic studies of
body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.
4. Mei L, Xiong W-C. Neuregulin 1 in neural development, synaptic plasticity and
5. Schizophrenia Bull. 2018;43:486.
6. Ruiz G, Bernal-Morales B. Myristic acid produces anxiolytic-like effects in wistar rats.
Neurosci. 2018;38:4889–904.
7. National Research Council. Guide for the Care and Use of Laboratory Animals.
Washington, DC: National Academy Press; 1996.
8. Kalam-San, I, Lekaisi N, Tisseau S, Jabri B, et al. Neuregulin1 and ErbB3 signaling
in the hypothalamic–pituitary–adrenocortical axis. Endocr Rev. 1991;12:118–34.
9. Huang A, Strother EK, Kugler AJ, Kriegstein AR, Donoghue JP. Experimental
evidence that myelination occurs in regions of the adult human brain free of
axonal pathways. Brain Behav Immun. 1999;13:372–84.
10. Using in vivo MRI to examine myelination in the adult human brain. Brain Behav
Immun. 2015;518:197–210.
11. Using in vivo MRI to examine myelination in the adult human brain. Brain Behav
Immun. 2015;518:197–210.
114. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238–49.

115. Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, Dellaioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1529.

116. Jiang Y, Liu Y, Zhu C, Ma X, Ma L, Zhou L, et al. Minocycline enhances hippocampal memory, neuroplasticity and synapse-associated proteins in aged C57 BL/6 mice. Neurobiol Learn Mem. 2015;121:20–29.

117. Fisher ffofliott M, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59:2781–9.

118. Wang X, Zhu L, Hu J, Guo R, Ye S, Liu F, et al. FGF21 attenuated LPS-induced depressive-like behavior via inhibiting the inflammatory pathway. Front Pharm. 2020;11:154.

119. Chen Y-J, Zhang M, Yin D-M, Wen L, Ting A, Wang P, et al. ErbB4 in parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-term potentiation. Proc Natl Acad Sci. 2010;117:21818–22.

120. Kaphzan H, Hernandez P, Jung JI, Cowansage KK, Deinhardt K, Chao MV, et al. Reversal of impaired hippocampal long-term potentiation and contextual fear memory deficits in angelman syndrome model mice by ErbB inhibitors. Biol Psychiact. 2012;72:182–90.

121. Lu Y, Sun X-D, Hou F-Q, Bl-L, Yin D-M, Liu F, et al. Maintenance of GABAergic activity by neuregulin 1-ErbB4 in amygdala for fear memory. Neuron. 2014;84:835–46.

122. Sobesky JL, Barrientos RM, May HSD, Thompson BM, Watkins LR, et al. High-fat diet consumption disrupts memory and primes elevations in hippocampal IL-1β, an effect that can be prevented with dietary reversal or IL-1 receptor antagonism. Brain Behav Immun. 2014;42:22–32.

123. Guillomet-Legris O, Muccioli GG. Obesity-induced neuroinflammation: beyond the hypothalamus. Trends Neurosci. 2017;40:237–53.

124. Dimayuga FO, Ding Q, Keller JN, Marchionni MA, Seroogy KB, Bruce-Keller AJ. The neuregulin GGF2 attenuates free radical release from activated microglial cells. J Neuroimmunol. 2003;136:67–74.

125. Shahriary GM, Kataria H, Karimi-Abdolrezae S. Neuregulin-1 fosters supportive interactions between microglia and neural stem/progenitor cells. Stem Cells Int. 2019;2019:1.

126. Beynon SB, Walker FR. Microglial activation in the injured and healthy brain. What are we really talking about? Practical and theoretical issues associated with the measurement of changes in microglial morphology. Neuroscience. 2012;2225:162–71.

127. Paolicelli RC, Bolosco G, Pagani F, Maggi L, Sciami N, Panzanelli P, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333:1456–8.

128. Sierra A, Encinas JM, Deudero JIP, Chancey JH, Enikolopov G, Overstreet-Wadiche LS, et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell. 2010;7:483–95.

129. Morrison H, Young K, Qureshi M, Rowe RK, Lifshitz J. Quantitative microglia analyses reveal diverse morphologic responses in the rat cortex after diffuse brain injury. Sci Rep-uk. 2017;7:13211.

130. Tam WY, Ma CHE. Bipolar/rod-shaped microglia are proliferating microglia with distinct M1/M2 phenotypes. Sci Rep-uk. 2014;4:7279.

131. Zieba J, Morris MJ, Weickert CS, Karl T. Behavioural effects of high fat diet exposure starting in late adolescence in neuregulin 1 transmembrane domain mutant mice. Behav Brain Res. 2019;373:112074.

132. Holm-Hansen S, Low JK, Zieba J, Gjedde A, Bergeren LH, Karl T. Behavioural effects of high fat diet in a mutant mouse model for the schizophrenia risk gene neuregulin 1. Genes Brain Behav. 2016;15:295–304.

133. Zieba J, Morris MJ, Weickert CS, Karl T. Behavioural effects of high fat diet in adult Ngr1 type III transgenic mice. Behav Brain Res. 2019;377:112217.

134. Cai C, Lin M, Xu Y, Li X, Yang S, Zhang H. Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study. BMC Med. 2016;14:165.